Skip to main content
Loading

Drusolv Therapeutics, Inc.

October 18, 2023
Franciscan D
Ophthalmology
Drusolv Therapeutics is a clinical-stage drug company based in Philadelphia. We are repurposing oral atorvastatin (using a novel formulation) for the new indication of early intervention in age-related macular degeneration (AMD). Our target is patients who are still in the intermediate stages of the disease and currently have very limited options to prevent progression to late-stage blindness. This is a $13bn per year, completely unmet need.
Speakers
John Edwards - Drusolv Therapeutics, Inc.